# Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

> **NCT06043388** · PHASE1 · UNKNOWN · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06043388
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09
- **Primary completion:** 2023-12
- **Final completion:** 2024-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06043388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06043388, "Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06043388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*